Table 3.
Duration of survival, response to therapy, and treatment characteristics in first- and second-line therapies.
| Overall treatment patterns and characteristics | First-line therapy patients (N=503) | Second-line therapy patientsa (N=503) |
|---|---|---|
| Duration and survivalb | ||
| Median duration of therapy, days (n=487c) | — | 130 |
| Median time to progression, days (n=304d,e) | — | 113 |
| Median duration of survival, days (n = 487c) | — | 153 |
|
| ||
| Time from first-line to second-line therapy (days), mean (SD) medianf | 77 (132) 24 | |
|
| ||
| Best response to therapy, n (%) | ||
| Complete response | 84 (16.7) | 13 (2.6) |
| Partial response | 205 (40.8) | 95 (18.9) |
| Stable response | 104 (20.7) | 193 (38.4) |
| Progression | 94 (18.7) | 155 (30.8) |
| Unknown | 16 (3.2) | 47 (9.3) |
|
| ||
| Performance status (ECOG), mean (SD)g | 1.15 (0.7) | 1.60 (0.7) |
|
| ||
| Enrolled in clinical trial, n (%) | 6 (1.2) | 11 (2.2) |
|
| ||
| Maximum number of treatment cycles, mean (SD)h | 5.9 (3.3) | 5.6 (3.8) |
|
| ||
| Reasons for ending therapy among patients who discontinued use of at least one agent, n (%)i | ||
| Disease progression | 288 (57.3) | 86 (28.6) |
| End conformed to treatment protocol | 176 (35.0) | 11 (3.7) |
| Patient refusal to continue treatment protocol | 41 (8.2) | 12 (4.0) |
| Adverse event/toxicity | 29 (5.8) | 9 (3.0) |
| Lack of benefit | 23 (4.6) | 7 (2.3) |
| Cost | 8 (1.6) | 1 (0.3) |
| Other, unknown, and missing | 24 (4.8) | 190 (63.1) |
Collection of patient data was restricted to those patients who received first- and second-line therapies.
Measured from start of second-line therapy.
Sixteen patients with invalid death dates were excluded.
Additional patients who ended a therapy for unknown reasons were excluded; four patients’ time to progression was censored by death.
Kaplan–Meier analyses were conducted for patients who had ongoing second-line therapy or who ended second-line therapy and gave at least one reason for ending therapy and had a valid death date.
Average number of days from end date of last agent in first-line therapy to start date of first agent administered in second-line therapy.
Karnofsky scores were converted to ECOG scores (ECOG 0 = KS 90–100; ECOG 1 = KS 70–80; ECOG 2 = KS 50–60; ECOG 3 = KS 30–40; ECOG 4 = KS 10–20). Twenty-six patients during first-line therapy and 31 patients during second-line therapy had unknown performance status.
Greatest number of cycles reported for any first- or second-line agent.
If ever reported for any first- or second-line agent. Multiple reasons for ending therapy could have been recorded. Patients with ongoing second-line therapy were excluded.
ECOG, Eastern Cooperative Oncology Group; GB, glioblastoma; KS, Karnofsky score.